movement efforts program. and clinical as update Thank congenital of Parkinson's as adrenal to good you, disorder Huntington's and in I'm Matt, hyperplasia disease our and support on programs Phase for happy I this provide our dyskinesia, well disease, afternoon. quarter an tardive
data Movement third presentations with to from Biosciences improving quarter, presented the healthcare opicapone Congress patients and to Congress Neurocrine VY-AADC the International Disorders. living our and Parkinson's commitment In The providers this movement and INGREZZA, reinforce Disease of the disorders. educating of at lives at
demonstrating XX-milligram broad abnormal patient For dyskinesia benefits patients a clinical dose of half data INGREZZA, patients greater than presented a taking showed XX% of and with significant XX-milligram robust presented INGREZZA. clinically Pool's long-term of improvement once-daily we tardive data XX-milligram range trial for more subset. dose both across the in Furthermore, strength in and movements in than
in considered provide with additional dose favorable generally when efficacy, study the XX-milligram These deutetrabenazine, published should treatment aggregate pool's that to this treatment in dyskinesia. healthcare equivalency It clinical important addition, using of which INGREZZA important tardive dose results. differences however choice trial at an August, be we inform particularly note In for in that versus and valbenazine the level. of was in and professionals deutetrabenazine information data, with demonstrated is to dose in indirect dose patients over valbenazine interpreting selection data comparison titration
to demonstrating of in resulted with catechol-O-methyltransferase our program. patients disease Parkinson's disease and inhibition At the we once-daily prolonged in opicapone, presented dosing on MDS, now Moving data enzyme. Parkinson's substantial that
reduced a breakdown, dyskinesia. enzyme to patients with without regulatory to For of XXXX. troublesome a resulting for remain XX, perspective fluctuations, track Parkinson's levodopa From we time date on of April motor allowing prevents experiencing on in increased PDUFA converted this more opicapone, the inhibition brain important in levodopa dopamine be for thus off-time
For by presented and the the with patients the of stage. in VY-AADC program, of VY-AADC we administration improved acquired Phase data disease strategic a open-label severity, through data a overall These longitudinal PD-XXXX. that modified gene therapy disease MDS, trial collaboration Hoehn our stage assessed Therapeutics, demonstrate Xb analysis Voyager from patients' Parkinson's treated at single for as Yahr
engagement to continue gene plan. registration to Voyager our gain VY-AADC the clarity work II at the before on closely FDA with We including the program, colleagues with Phase to progress year-end further therapy
ataxia also QX, Friedreich's Therapeutics subsequent programs to bring targeting continue work and Voyager forward targets. novel to During we two with neurological
in will other our endpoint Huntington's Phase programs. beginning disease. between Huntington's centers Disease valbenazine month. to approximately of This development Last multiple XXX across subjects a now we this U.S. Turning from Maximal Chorea change in clinical for of baseline KINECT-HD month, the study III trial Total initiated the Rating Unified in enroll treatment efficacy valbenazine The Scale the primary compares score and placebo. Chorea
pleased We the completion are of with this during in implementation Huntington's XXXX. the be design the and and to of study collaborating study anticipate group study
adult on made study is adaptive we of QX. scientific a present to The Phase hyperplasia, adrenal congenital progress during from For at intend proof-of-concept in CAH and NBI-XXXXX this meeting fronts nearing several study II with we completion, subjects XXXX. data during
trial design the plan on with FDA We're in the had subjects regulators the process registration the this initiating U.S. registrational currently global the of required of intent alignment a with adult CAH to program. in during also CAH reviewing trial outside adult mid-XXXX. for discussions obtain We with with the
Finally, our vesicular for neuroscience a Phase inhibitor X continues in internally I transporter with in treatment the use evaluation. range monoamine discovered of potential disorders of
With for teams in support very our I'll call the back progress quarter, that, the Kevin. want I'm pleased and of to the their summary, cross-functional thank In in work our to pipeline with this hand hard portfolio.
